Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, Oliver Hahn, Thomas Büttner, Florian Roghmann, Christian Bolenz, Friedemann Zengerling, Constantin Schwab, Dora Nagy, Marieta Toma, Glen Kristiansen, Hendrik Heers, Philipp Ivanyi, Günter Niegisch, Camilla Marisa Grunewald, Christopher Darr, Arian Farid, Katrin Schlack, Mahmoud Abbas, Can Aydogdu, Jozefina Casuscelli, Theresa Mokry, Michael Mayr, Dora Niedersüß-Beke, Steffen Rausch, Dimo Dietrich, Jonas Saal, Jörg Ellinger, Manuel Ritter, Abdullah Alajati, Christoph Kuppe, Joshua Meeks, Francisco E Vera Badillo, J Alberto Nakauma-González, Joost Boormans, Kerstin Junker, Arndt Hartmann, Viktor Grünwald, Michael Hölzel, Markus Eckstein
PURPOSE: The anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit is only achieved in a small, yet uncharacterized patient subset. NECTIN4 is located on chromosome 1q23.3, and 1q23.3 gains represent frequent copy number variations (CNVs) in urothelial cancer. Here, we aimed to evaluate NECTIN4 amplifications as a genomic biomarker to predict EV response in patients with mUC. MATERIALS AND METHODS: We established a NECTIN4 -specific fluorescence in situ hybridization (FISH) assay to assess the predictive value of NECTIN4 CNVs in a multicenter EV-treated mUC patient cohort (mUC-EV, n = 108)...
April 24, 2024: Journal of Clinical Oncology
#2
JOURNAL ARTICLE
Shiori Tohyama, Yoshiya Horimoto, Yumiko Ushiyama, Ryoko Semba, Shiori Hotchi, Naomi Sugano, Kanako Ogura, Fumi Murakami
BACKGROUND: The age of onset of the phyllodes tumor is generally in the late 40 s, and diagnosis and treatment during pregnancy and lactation are rare. We herein present a case of a phyllodes tumor that rapidly increased in size during the pregnancy and lactation period. CASE PRESENTATION: A 39-year-old woman was referred to our hospital with a mass in the right breast that increased in size during the pregnancy and lactation period. On ultrasound (5 week postpartum), a well-defined lobulated mass with internal septations and fluid retention was observed...
April 24, 2024: Surgical Case Reports
#3
JOURNAL ARTICLE
Daniah Alsaadi, Lyndon Low, James Ting, Michael Craughwell, John McDonnell, Aoife Lowery, Karl Sweeney
Minimization of intra-operative opioid use is an area of ongoing research interest with several potential benefits to the patient. Pre-emptive analgesia, defined as the administration of an analgesic before surgery to prevent establishment of central sensitization of pain, is one avenue that has been explored to achieve this. A retrospective observational study was undertaken to examine the effect of pre-emptive paracetamol on intra-operative opioid requirements. The medical and operative data of 156 patients who underwent day-case wide local excision and sentinel lymph node biopsy with and without regional block surgery at our center between October 2019 and May 2022 was carried out...
2024: EXCLI Journal
#4
JOURNAL ARTICLE
Sudhir Kumar Chauhan, Claire Dunn, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Gjertrud Skorstad, Adam Sike, Bjørnar Gilje, Sunil Xavier Raj, Kanutte Huse, Bjørn Naume, Jon Amund Kyte
Immunotherapies blocking the PD-1/PD-L1 checkpoint show some efficacy in metastatic breast cancer (mBC) but are often hindered by immunosuppressive mechanisms. Understanding these mechanisms is crucial for personalized treatments, with peripheral blood monitoring representing a practical alternative to repeated biopsies. In the present study, we performed a comprehensive mass cytometry analysis of peripheral blood immune cells in 104 patients with HER2 negative mBC and 20 healthy donors (HD). We found that mBC patients had significantly elevated monocyte levels and reduced levels of CD4+ T cells and plasmacytoid dendritic cells, when compared to HD...
April 23, 2024: NPJ Breast Cancer
#5
JOURNAL ARTICLE
Chia Yew Kong, Jacob Williams, Niroshini Hemadasa, Dermot Murphy, Maria Bews-Hair
BACKGROUND: Magtrace is a supraparamagnetic iron lymphatic tracer that has had increasing use in sentinel node biopsy (SNB) for breast cancer and has theoretical logistical benefits in centres where nanocolloid use may be associated with such issues. We describe our initial experience with the introduction of Magtrace into our routine practice by dual localisation with nanocolloid, comparing performance, and concordance. MATERIALS AND METHODS: This was prospective study of the first patients undergoing axillary SNB using Magtrace in a single centre...
March 30, 2024: Clinical Breast Cancer
#6
JOURNAL ARTICLE
Akiko Ogiya, Kiyomi Kimura, Takayuki Ueno, Takuji Iwase, Shinji Ohno
PURPOSE: To clarify how body mass index (BMI) affects the development and temporal trend of breast cancer-related lymphedema (BCRL). METHODS: This is a prospective study in which patients with operable breast cancer were registered in a single institute between November 2009 and July 2010. The incidence of lymphedema at 1, 3, and 5 years after surgery was assessed according to BMI, and the trend of newly developed BCRL was examined. Obesity was defined as BMI ≥25 in accordance with the Japan Society for the Study of Obesity...
April 16, 2024: European Journal of Surgical Oncology
#7
JOURNAL ARTICLE
Hannah Oh, Lusine Yaghjyan, Yujing J Heng, Bernard Rosner, Matt B Mahoney, Divya Murthy, Gabrielle M Baker, Rulla M Tamimi
BACKGROUND: According to the stem cell hypothesis, breast carcinogenesis may be related to the breast stem cell pool size. However, little is known about associations of breast cancer risk factors, such as anthropometric measures, with the expression of stem cell markers in non-cancerous breast tissue. METHODS: The analysis included 414 women with biopsy-confirmed benign breast disease (BBD) in the Nurses' Health Study (NHS) and NHSII. Birthweight, weight at age 18, current weight, and current height were reported via self-administered questionnaire...
April 23, 2024: Cancer Epidemiology, Biomarkers & Prevention
#8
JOURNAL ARTICLE
Nahla M Badr, Mohamed Zaakouk, Qi Zhang, Daniel Kearns, Anthony Kong, Abeer M Shaaban
BACKGROUND: There are limited data on the role of multigene tests and their correlation with immunohistochemistry (IHC), especially on core biopsy. MammaTyper is a quantitative conformite Europeeanne (CE) marked, National Institute for Health and Care excellence (NICE) approved, in in vitro diagnostic quantitative real-time polymerase chain reaction (RT-qPCR) test for assessment of mRNA expression of four biomarkers (ESR1, PGR, ERBB2, MKI67). METHODS: We evaluated the concordance of MammaTyper with oestrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67 by IHC on 133 core needle biopsies of breast cancer...
April 23, 2024: Histopathology
#9
Chinedum Okafor, Jehan Abdulsattar, Adaugo Nwanguma
Breast granular cell tumors, which are benign and rare tumors of the breast, pose a diagnostic challenge due to their rarity and nuanced clinical presentations. This article explores a unique case of a 41-year-old female with a biopsy-confirmed granular cell tumor, shedding light on the intricacies involved in diagnosis. Rooted in a neuroectodermal origin, particularly Schwann cells, these tumors demand a multidimensional diagnostic approach for accurate identification. Despite their predominantly benign nature, malignant variants exist, necessitating a thorough histomorphology examination, supported by immunohistochemistry, for precise classification...
March 2024: Curēus
#10
JOURNAL ARTICLE
Samuel A Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J Montero, Corey Lipchik, Melanie Finnigan, Rachel C Jankowitz, Mohamad A Salkeni, Sai K Maley, Shannon L Puhalla, Fanny Piette, Katie Quinn, Kyle Chang, Rebecca J Nagy, Carmen J Allegra, Kelly Vehec, Norman Wolmark, Peter C Lucas, Ashok Srinivasan, Katherine L Pogue-Geile
BACKGROUND: We previously reported our phase Ib trial, testing the safety, tolerability, and efficacy of T-DM1 + neratinib in HER2-positive metastatic breast cancer patients. Patients with ERBB2 amplification in ctDNA had deeper and more durable responses. This study extends these observations with in-depth analysis of molecular markers and mechanisms of resistance in additional patients. METHODS: Forty-nine HER2-positive patients (determined locally) who progressed on-treatment with trastuzumab + pertuzumab were enrolled in this phase Ib/II study...
April 22, 2024: Breast Cancer Research: BCR
#11
REVIEW
S Peters, S Loi, F André, S Chandarlapaty, E Felip, S P Finn, P A Jänne, K M Kerr, E Munzone, A Passaro, M Pérol, E F Smit, C Swanton, G Viale, R A Stahel
Following the approval of the first antibody-drug conjugates (ADCs) in the early 2000s, development has increased dramatically, with 14 ADCs now approved and >100 in clinical development. In lung cancer, trastuzumab deruxtecan (T-DXd) is approved in human epidermal growth factor receptor 2 (HER2)-mutated, unresectable or metastatic non-small cell lung cancer, with ADCs targeting HER3 (patritumab deruxtecan), trophoblast cell-surface antigen 2 (datopotamab deruxtecan and sacituzumab govitecan [SG]) and mesenchymal-epithelial transition factor (telisotuzumab vedotin) in late-stage clinical development...
April 20, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
#12
JOURNAL ARTICLE
Eric A Roach, Christopher R Weil, George Cannon, Jon Grant, Margaret Van Meter, Dustin Boothe
BACKGROUND: For breast cancer with advanced regional lymph node involvement, axillary lymph node dissection (ALND) remains the standard of care for staging and treating the axilla despite the presence of undissected lymph nodes. The benefit of ALND in this setting is unknown. OBJECTIVES: We sought to describe national patterns of care of axillary surgery and its association with overall survival (OS) among women with cN2b-N3c breast cancer who receive adjuvant radiotherapy...
April 22, 2024: Annals of Surgical Oncology
#13
JOURNAL ARTICLE
Yuko Tanaka, Yuki Ohshima, Yumi Fukaya, Keiko Hosoya, Makoto Wakahara
A 61-year-old woman presented at a nearby clinic with a complaint of a mass in the right axilla. Initial imaging examinations, including mammography, ultrasonography, and breast MRI, did not reveal any obvious intramammary lesions, although a swollen lymph node was observed in the right axilla. Fine-needle aspiration cytology confirmed malignancy. Hence, a core needle biopsy was performed. The results indicated a suspected metastasis of invasive ductal carcinoma(ER-, PgR-, HER2-); however, the primary tumor could not be definitively determined...
April 2024: Gan to Kagaku Ryoho. Cancer & Chemotherapy
#14
JOURNAL ARTICLE
Michael R Boland
Surgical management of the axilla has evolved considerably in recent years, with a strong focus on de-escalation to minimise morbidity whilst maintaining oncological outcomes. Current trials will focus on the omission of Sentinel node biopsy in select groups of patients, while axillary lymph node dissection will be reserved for those with more aggressive disease.
April 21, 2024: Journal of Surgical Oncology
#15
JOURNAL ARTICLE
Sei Na, Milim Kim, Yujun Park, Hyun Jung Kwon, Hee-Chul Shin, Eun-Kyu Kim, Mijung Jang, Sun Mi Kim, So Yeon Park
BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-low status has recently gained attention because of the potential therapeutic benefits of antibody-drug conjugates (ADCs) in breast cancer patients. We aimed to investigate the concordance of HER2 status between core needle biopsy (CNB) and subsequent surgical resection specimens focusing on the HER2-low status. METHODS: This retrospective study was conducted in 1,387 patients with invasive breast cancer whose HER2 status was evaluated in both CNB and surgical resection specimens...
April 21, 2024: Breast Cancer: the Journal of the Japanese Breast Cancer Society
#16
JOURNAL ARTICLE
Robert Hsu, Batul Al-Zubeidy, Daniel Flores, Ari Nazarian, Aaron Baugh, Edgar Gonzalez, Sofi Castanon, Joanne Xiu, Irene Kang, Darcy Spicer, Heinz Josef Lenz, Lily Dara, Foluso O Ademuyiwa, W Michael Korn, Sheeba Irshad, Isaac S Chan, Evanthia T Roussos Torres
PURPOSE: Programmed death receptor ligand-1 (PD-L1) expression and tumor mutational burden (TMB) are approved screening biomarkers for immune checkpoint inhibition (ICI) in advanced triple negative breast cancer. We examined these biomarkers along with characterization of the tumor microenvironment (TME) between breast tumors (BrTs), axillary metastases (AxMs), liver metastases (LvMs), non-axillary lymph node metastases, and non-liver metastases to determine differences related to site of metastatic disease...
April 20, 2024: Breast Cancer Research and Treatment
#17
REVIEW
Bruce Gao, Antonio R H Gorgen, Rohit Bhatt, Zachary E Tano, Kalon L Morgan, Kelvin Vo, Sina Soltanzadeh Zarandi, Sohrab N Ali, Pengbo Jiang, Roshan M Patel, Ralph V Clayman, Jaime Landman
Current guidelines do not mandate routine preoperative renal mass biopsy (RMB) for small renal masses (SRMs), which results in a considerable rate (18%-26%) of needless nephrectomy/partial nephrectomy for benign renal tumors. In light of this ongoing practice, a narrative review was conducted to examine the role of routine RMB for SRM. First, arguments justifying the current non-biopsy approach to SRM are critically reviewed and contested. Second, as a standalone procedure, RMB is critically assessed; RMB was found to have higher sensitivity, specificity, and an equal or lower complication rate when compared with other commonly preoperatively biopsied solid organ tumors (e...
April 19, 2024: Urologic Oncology
#18
JOURNAL ARTICLE
Anila Sharma, Gurudutt Gupta, Vikas Nishadham, Akanksha Malik, Ankur Kumar, Sunil Pasricha, Meenakshi Kamboj, Garima Durga, Anurag Mehta
Surgical pathology reports may undergo revisions broadly categorized as addenda (supplementary information) or amendments (changes to finalized reports). Amendments indicate potential flaws in the diagnostic process and serve as important indicators of vulnerabilities in the histopathology workflow. This study analyzed the frequency and distribution of amendments in surgical pathology reports over 8 years to identify patterns highlighting opportunities for improvement. Surgical biopsies, excisions, and resections were included; cytology and molecular tests were excluded...
April 16, 2024: Annals of Diagnostic Pathology
#19
JOURNAL ARTICLE
Siyi Luo, Xinyue Zhang, Zhichun Wang
BACKGROUND: Mucosa-associated lymphoid tissue (MALT) lymphoma, also known as extranodal marginal zone lymphoma, is more commonly detected in the stomach and rarely in the breast. Our study presented a clinical and pathological examination of a patient diagnosed with breast MALT lymphoma, supplemented with pertinent research, to offer guidance for the diagnosis and treatment of this condition. PEOPLE CONCERNS: The occurrence of breast MALT lymphoma has risen in the past decade, but its etiology, progression and treatment response are less well-studied...
April 19, 2024: Medicine (Baltimore)
#20
JOURNAL ARTICLE
Hang Li, Guoliang Zhang, Hongling Wang, Haiying Chen, Xiaoli Liu, Chuansheng Zheng, Lisheng Lin, Lihong Li
BACKGROUND: Idiopathic granulomatous mastitis (IGM) results in notable clinical symptoms and breast deformity. This study aimed to evaluate the clinical feasibility of microwave ablation (MWA) for the treatment of IGM through comparison with surgical excision. METHODS: From June 2016 to December 2020, a total of 234 consecutive patients admitted to the hospital were retrospectively included in this study. IGM was pathologically confirmed via breast biopsy in all included patients...
April 18, 2024: BMC Women's Health
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
